000071011 001__ 71011
000071011 005__ 20180622124306.0
000071011 0247_ $$2doi$$a10.1089/mdr.2013.0109
000071011 0248_ $$2sideral$$a85992
000071011 037__ $$aART-2014-85992
000071011 041__ $$aeng
000071011 100__ $$aGarrido, A.
000071011 245__ $$aCharacterization of plasmid-mediated beta-lactamases in fecal colonizing patients in the hospital and community setting in Spain
000071011 260__ $$c2014
000071011 5060_ $$aAccess copy available to the general public$$fUnrestricted
000071011 5203_ $$aAim: Active surveillance of plasmid-mediated ß-lactamase-producing Enterobacteriaceae (PMBL-E) in fecal carriers in the hospital and in the community setting in a non-outbreak period of time.
Methods: Patients were screened for carriage of Enterobacteriaceae resistant to expanded-spectrum cephalosporins and PMBL-E were characterized (extended-spectrum-ß-lactamase [ESBL], plasmid-mediated AmpC ß-lactamase [pAmpC], and carbapenemases) by PCR and sequencing.
Results: The prevalence of ESBL and pAmpC carriers was 5.06% and 0.59%, respectively. Overall, CTX-M-like enzymes were the ESBL dominate enzymes (96.15%). The group CTX-M-9 was the most prevalent (81, 54%) [CTX-M-14 (74, 91.35%), CTX-M-9 (5, 6.17%), CTX-M-24 (1, 1.23%), and CTX-M-27 (1, 1.23%)] followed by the group CTX-M-1 (64, 42.67%) [CTX-M-15 (42, 65.63%), CTX-M-1 (13, 20.31%), CTX-M-32 (8, 12.5%), and CTX-M-3 (1, 1.56%)]. One CTX-M-10, one CTX-M-59, and three CTX-M-8 were also found. A very small representation of SHV or TEM ESBL enzymes was found (3.2% and 0.64%, respectively). pAmpC characterization revealed a predominance of CMY-2 (81.25%), followed by DHA-1 (18.75%). We did not detect the presence of carbapenemase producers.
Conclusions: The prevalence of ESBL-producers from fecal carriers is stable in our area, but colonization by pAmpC producers has emerged recently as we have confirmed. Periodic active surveillance is useful to identify these human reservoirs and control the evolution of PMBL carriage in a community over time.
000071011 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B24-211130
000071011 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000071011 590__ $$a2.49$$b2014
000071011 591__ $$aPHARMACOLOGY & PHARMACY$$b116 / 255 = 0.455$$c2014$$dQ2$$eT2
000071011 591__ $$aINFECTIOUS DISEASES$$b42 / 78 = 0.538$$c2014$$dQ3$$eT2
000071011 591__ $$aMICROBIOLOGY$$b62 / 119 = 0.521$$c2014$$dQ3$$eT2
000071011 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000071011 700__ $$0(orcid)0000-0002-9742-1463$$aSeral, C.$$uUniversidad de Zaragoza
000071011 700__ $$aGude, M.J.
000071011 700__ $$aCasado, C.
000071011 700__ $$aGonzález-Domínguez, M.
000071011 700__ $$aSáenz, Y.
000071011 700__ $$0(orcid)0000-0002-2519-701X$$aCastillo F.J.$$uUniversidad de Zaragoza
000071011 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDepartamento de Microbiología, Medicina Preventiva y Salud Pública$$cMicrobiología
000071011 773__ $$g20, 4 (2014), 301-304$$pMicrob. drug resist.$$tMicrobial Drug Resistance$$x1076-6294
000071011 8564_ $$s118274$$uhttps://zaguan.unizar.es/record/71011/files/texto_completo.pdf$$yVersión publicada
000071011 8564_ $$s109176$$uhttps://zaguan.unizar.es/record/71011/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000071011 909CO $$ooai:zaguan.unizar.es:71011$$particulos$$pdriver
000071011 951__ $$a2018-06-22-11:08:29
000071011 980__ $$aARTICLE